Similar Outcomes for IPF Patients Found for Esbriet, Ofev in Analysis
People with idiopathic pulmonary fibrosis (IPF) had the same mortality and hospitalization rates, and incurred similar healthcare costs, whether they were treated with Esbriet (pirfenidone) or Ofev (nintedanib), a German insurance claims analysis showed. However, the analysis — conducted over five years and involving more than 1,000 patients…